Here's Why CRISPR Therapeutics AG (CRSP) is a Great Momentum Stock to BuyZacks Investment Research • 11/29/23
What's Next For Gene-Editing Darling Crispr After Its 'Historic' First-Ever Approval?Investors Business Daily • 11/29/23
5 Biotech Stocks Likely to Thrive as Industry Prospects Look BrightZacks Investment Research • 11/22/23
Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to TradeZacks Investment Research • 11/20/23
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?The Motley Fool • 11/19/23
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing DrugInvestors Business Daily • 11/16/23
Crispr Therapeutics, Vertex get world's first regulatory green light for CRISPR-based medicineMarket Watch • 11/16/23
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.The Motley Fool • 11/16/23
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 11/16/23